tiprankstipranks
Advertisement
Advertisement
Longeveron provides update on laromestrocel development after Type C meeting
PremiumThe FlyLongeveron provides update on laromestrocel development after Type C meeting
13d ago
Longeveron Updates FDA Path for ELPIS II Trial
Premium
Company Announcements
Longeveron Updates FDA Path for ELPIS II Trial
13d ago
Longeveron price target lowered to $8 from $10 at H.C. Wainwright
Premium
The Fly
Longeveron price target lowered to $8 from $10 at H.C. Wainwright
17d ago
Longeveron Receives Extended Nasdaq Compliance Grace Period
PremiumCompany AnnouncementsLongeveron Receives Extended Nasdaq Compliance Grace Period
2M ago
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote
Premium
Company Announcements
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote
2M ago
Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure
Premium
Company Announcements
Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure
2M ago
Longeveron prices 6.01M shares at 52c in private placement
PremiumThe FlyLongeveron prices 6.01M shares at 52c in private placement
2M ago
LGVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
LGVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
Longeveron: Phase 2b results show laromestrocel improved physical condition
Premium
The Fly
Longeveron: Phase 2b results show laromestrocel improved physical condition
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100